M. Diefenhardt

TNT is increasingly considered the preferred treatment strategy, especially for patients with MRI-defined high-risk rectal cancer, and organ-preserving (“watch-and-wait”) strategies are increasingly favored and continue to be refined in ongoing clinical trials.